Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
- 22 September 2007
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 154 (4), 624-631
- https://doi.org/10.1016/j.ahj.2007.06.024
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Usefulness of Enalapril Versus Propranolol or Atenolol for Prevention of Aortic Dilation in Patients With the Marfan SyndromeThe American Journal of Cardiology, 2005
- Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndromeNature Genetics, 2003
- Latent Transforming Growth Factor β-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated ProteinJournal of Biological Chemistry, 2003
- Growth and maturation in Marfan syndromeAmerican Journal of Medical Genetics, 2002
- Role of the Latent Transforming Growth Factor β–Binding Protein 1 in Fibrillin-Containing Microfibrils in Bone Cells In Vitro and In VivoJournal of Bone and Mineral Research, 2000
- Replacement of the Aortic Root in Patients with Marfan's SyndromeNew England Journal of Medicine, 1999
- Latent transforming growth factor-β: Structural features and mechanisms of activationKidney International, 1997
- Life expectancy in the Marfan syndromeThe American Journal of Cardiology, 1995
- Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndromeThe American Journal of Cardiology, 1994